Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in metastatic non-small cell lung cancer with activated PI3K pathway
2010-024011-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of buparlisib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Progression-free survival hazard ratio (BKM120 vs chemotherapy) and Objective response rate. Started Mar 2011; status: completed.
02
Drugs
buparlisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-024011-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024011-14.